FREQ News and Press, Frequency Therapeutics Inc. From 05/14/20

Frequency Therapeutics (NASDAQ: FREQ ): Q1 GAAP EPS of -$0.16 beats by $0.08 . More news on: Frequency Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Phase 2a Study of FX-322 for Sensorineural Hearing Loss Continues Enrollment at Multiple Sites Shares Top-Line Data from Exploratory Clinical Study Confirming Delivery of FX-322 to the Cochlea Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company...

Top-Line Results Show Consistent Drug Entry in All Patients Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Frequency Therapeutics (NASDAQ: FREQ ): Q4 GAAP EPS of -$0.19 misses by $0.26 . More news on: Frequency Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Phase 2a Study of FX-322 for Sensorineural Hearing Loss Remains Ongoing Strong Cash Position at End of 2019 Providing Runway into 2022; Potential for Meaningful FX-322 Development Milestones Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company fo...

The following slide deck was published by Frequency Therapeutics, Inc. in conjunction with this Read more ...

Initial public offerings offer public market investors the earliest chance to own a piece of a promising company. Capital-intensive fields like drug development have continued to witness a stream of IPOs -- some more successful than others. Besides raising cash for company operations, a public ...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present ...

The following slide deck was published by Frequency Therapeutics, Inc. in conjunction with this Read more ...